Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 129, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2020.110512
Keywords
Transcatheter arterial chemoembolization; Liver tumor; Microspheres; Sorafenib; Catalase
Funding
- National Natural Science Foundation of China [81801100, 81972879]
- Natural Science Foundation of Jiangsu Province [BK20171124, BK20180130]
- Jiangsu Provincial Commission of Health and Family Planning [H2017049]
- Science and Technology Program of Nanjing [201803037]
- Medical Science and Technology Development Project of Nanjing
- Fundamental Research Funds for the Central Universities [021414380449]
Ask authors/readers for more resources
Background: Transcatheter arterial chemoembolization (TACE) is extensively used in the treatment of advanced on hepatocellular carcinoma (HCC). However, the efficacy of TACE is usually limited to secondary tumor hypoxia and hypoxia-related tumor angiogenesis. Methods: In this study, poly(lactic-co-glycolic acid) (PLGA) microspheres (SOR-CAT-PLGA MSs) encapsulating sorafenib (SOR) and catalase (CAT) were prepared by double-emulsion solvent diffusion method. Sorafenib inhibits tumor angiogenesis, and catalase decomposes hydrogen peroxide (H2O2) to generate oxygen in the tumor. Results: In vitro and in vivo, SOR-CAT-PLGA MSs could significantly improve the efficacy of hepatic artery embolization in the treatment of rabbit VX2 liver tumors, regulate tumor hypoxia and immunosuppressive microenvironment, then achieved near-complete and rapid necrosis of liver tumors. Conclusions: The application of new SOR-CAT-PLGA MSs in hepatic artery chemoembolization of rabbit VX2 liver tumor is a promising approach to improve the therapeutic effect of liver tumors and has a broad clinical application prospect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available